The COVID-19 pandemic presents unprecedented challenges to communities around the world. Members of the scientific and public health communities need to collaborate with each other now more than ever to tackle this disease. In response to the global COVID-19 pandemic, Clover entered into partnerships with the Coalition for Epidemic Preparedness Innovations (CEPI), GSK, and Dynavax for the advancement of its COVID-19 vaccine program. We aim to work with our partners to deliver safe and effective vaccines to all countries and regions affected by the pandemic.
Clover entered a development partnership with CEPI to accelerate clinical development and scale up manufacturing capacity for the S-Trimer COVID-19 vaccine programs. CEPI’s total investment in Clover’s S-Trimer COVID-19 vaccine program is up to $328 million to support manufacturing scale-up and clinical development through a global pivotal Phase 2/3 efficacy clinical study and potential licensure. In line with CEPI’s commitment to equitable access and Clover’s mission to contribute to the control of the pandemic, if proven to be safe and effective, the S-Trimer vaccine candidates will be procured and allocated through the COVID-19 Vaccine Global Access (COVAX) Facility. The COVAX Facility aims to ensure equitable access to COVID-19 vaccines for all countries, at all levels of development, that wish to participate.
In March 2020, Clover entered a research collaboration with Dynavax Technologies Corporation to evaluate Clover’s S-Trimer vaccine candidate with Dynavax’s CpG 1018 adjuvant plus alum in preclinical and clinical studies.
At Clover, we believe medical innovations that can truly make a difference to global health are often enabled by collaborations.
By joining forces with leading academic experts, biotech and pharmaceutical companies and NGOs/international organizations, we are constantly striving to maximize our impact and contributions to help solve the world’s most urgent public health needs and debilitating diseases.